CY1121049T1 - Καινοτομες αλληλουχιες σηματος για τη βελτιωση των πρωτεϊνικων εκφρασεων και της εκκρισης των ανασυνδυασμενων ενζυμων και αλλων πρωτεϊνων - Google Patents

Καινοτομες αλληλουχιες σηματος για τη βελτιωση των πρωτεϊνικων εκφρασεων και της εκκρισης των ανασυνδυασμενων ενζυμων και αλλων πρωτεϊνων

Info

Publication number
CY1121049T1
CY1121049T1 CY181100941T CY181100941T CY1121049T1 CY 1121049 T1 CY1121049 T1 CY 1121049T1 CY 181100941 T CY181100941 T CY 181100941T CY 181100941 T CY181100941 T CY 181100941T CY 1121049 T1 CY1121049 T1 CY 1121049T1
Authority
CY
Cyprus
Prior art keywords
signal sequences
bip
heavy chain
binding protein
disclosed
Prior art date
Application number
CY181100941T
Other languages
English (en)
Inventor
Hung Do
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of CY1121049T1 publication Critical patent/CY1121049T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Abstract

Αποκαλύπτονται πολυπεπτιδικές αλληλουχίες σήματος τροποποιημένων θραυσμάτων της ανθρώπινης συνδετικής πρωτεΐνης βαριάς αλυσίδας της ανοσοσφαιρίνης (Βip). Επίσης αποκαλύπτονται πρωτεΐνες σύντηξης που περιλαμβάνουν ένα τροποποιημένο θραύσμα της ανθρώπινης συνδετικής πρωτεΐνης βαριάς αλυσίδας της ανοσοσφαιρίνης (Βip) λειτουργικά συνδεδεμένης σ' ένα ετερόλογο πολυπεπτίδιο. Επίσης αποκαλύπτονται οχήματα πρωτεϊνικής έκφρασης που περιλαμβάνουν έναν προωθητή λειτουργικά συνδεδεμένο σε μία πρώτη αλληλουχία DNA που κωδικοποιεί μία αλληλουχία σήματος που περιλαμβάνει ένα τροποποιημένο θραύσμα της ανθρώπινης συνδετικής πρωτεΐνης βαριάς αλυσίδας της ανοσοσφαιρίνης (Βip) και μία δεύτερη αλληλουχία DNA που κωδικοποιεί ένα ετερόλογο πολυπεπτίδιο τηγμένο στο πλαίσιο της πρώτης αλληλουχίας DNA. Περαιτέρω αποκαλύπτονται μέθοδοι παραγωγής πολυπεπτιδίων, που περιλαμβάνουν την έκφραση μίας πρωτεΐνης σύντηξης που περιλαμβάνει πολυπεπτιδικές αλληλουχίες σήματος τροποποιημένων θραυσμάτων της ανθρώπινης συνδετικής πρωτεΐνης βαριάς αλυσίδας της ανοσοσφαιρίνης (Bip) λειτουργικά συνδεδεμένης σ' ένα ετερόλογο πολυπεπτίδιο και την ανάκτηση του ετερόλογου πολυπεπτιδίου.
CY181100941T 2010-11-22 2018-09-12 Καινοτομες αλληλουχιες σηματος για τη βελτιωση των πρωτεϊνικων εκφρασεων και της εκκρισης των ανασυνδυασμενων ενζυμων και αλλων πρωτεϊνων CY1121049T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41592610P 2010-11-22 2010-11-22
PCT/US2011/061862 WO2012071422A2 (en) 2010-11-22 2011-11-22 Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins

Publications (1)

Publication Number Publication Date
CY1121049T1 true CY1121049T1 (el) 2019-12-11

Family

ID=46146394

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100941T CY1121049T1 (el) 2010-11-22 2018-09-12 Καινοτομες αλληλουχιες σηματος για τη βελτιωση των πρωτεϊνικων εκφρασεων και της εκκρισης των ανασυνδυασμενων ενζυμων και αλλων πρωτεϊνων

Country Status (18)

Country Link
US (1) US9279007B2 (el)
EP (2) EP3461905B1 (el)
JP (1) JP2014503198A (el)
KR (2) KR101984318B1 (el)
CN (1) CN103328649B (el)
BR (1) BR112013012671B1 (el)
CA (1) CA2818689C (el)
CY (1) CY1121049T1 (el)
DK (2) DK2643468T3 (el)
ES (2) ES2829199T3 (el)
HR (1) HRP20181315T1 (el)
HU (1) HUE039070T2 (el)
LT (1) LT2643468T (el)
PL (1) PL2643468T3 (el)
PT (1) PT2643468T (el)
RS (1) RS57601B1 (el)
SI (1) SI2643468T1 (el)
WO (1) WO2012071422A2 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3680336A1 (en) * 2014-07-03 2020-07-15 F. Hoffmann-La Roche AG Polypeptide expression systems
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
WO2019108924A2 (en) 2017-11-30 2019-06-06 Amicus Therapeutics, Inc. Cdkl5 expression variants and cdkl5 fusion proteins
JP2021521851A (ja) 2018-04-30 2021-08-30 アミカス セラピューティックス インコーポレイテッド 遺伝子治療構築物及び使用方法
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US11097015B2 (en) 2018-10-10 2021-08-24 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
MX2021007241A (es) * 2018-12-19 2021-09-23 Versameb Ag Acido ribonucleico (arn) que codifica para una proteina.
JP2022524081A (ja) 2019-03-08 2022-04-27 オブシディアン セラピューティクス， インコーポレイテッド 調整可能な制御のためのヒトカルボニックアンヒドラーゼ２組成物及び方法
EP3983538A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN112342247B (zh) * 2020-11-10 2022-03-11 江苏科技大学 一种提高家蚕细胞表达外源蛋白分泌率的方法
MX2023006445A (es) 2020-12-01 2023-08-10 Univ Pennsylvania Composiciones y usos de estas para el tratamiento del síndrome de angelman.
WO2023086939A1 (en) 2021-11-12 2023-05-19 Amicus Therapeutics, Inc. Compositions and methods for treating mucopolysaccharidosis iiia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4892132B2 (ja) * 1998-11-24 2012-03-07 ブリストル−マイヤーズ スクイブ カンパニー ７０ｋＤ熱ショック蛋白による化合物の細胞内標的輸送
CA2545053C (en) * 2003-11-06 2016-04-19 Genencor International, Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
EP2007885B1 (en) * 2006-04-11 2010-07-21 CSL Behring GmbH Method of increasing the in vivo recovery of therapeutic polypeptides

Also Published As

Publication number Publication date
LT2643468T (lt) 2018-09-10
DK3461905T3 (da) 2020-11-02
WO2012071422A2 (en) 2012-05-31
BR112013012671A2 (pt) 2016-10-11
DK2643468T3 (en) 2018-09-24
BR112013012671B1 (pt) 2022-03-03
EP3461905A1 (en) 2019-04-03
CA2818689A1 (en) 2012-05-31
ES2687415T3 (es) 2018-10-25
CA2818689C (en) 2021-09-21
US20140045216A1 (en) 2014-02-13
KR20190060888A (ko) 2019-06-03
EP2643468B1 (en) 2018-07-04
KR20130121878A (ko) 2013-11-06
RS57601B1 (sr) 2018-11-30
EP2643468A4 (en) 2014-12-24
SI2643468T1 (sl) 2018-10-30
PL2643468T3 (pl) 2018-11-30
HRP20181315T1 (hr) 2018-10-19
EP2643468A2 (en) 2013-10-02
ES2829199T3 (es) 2021-05-31
KR101984318B1 (ko) 2019-05-31
US9279007B2 (en) 2016-03-08
CN103328649A (zh) 2013-09-25
EP3461905B1 (en) 2020-08-05
HUE039070T2 (hu) 2018-12-28
WO2012071422A3 (en) 2012-08-02
JP2014503198A (ja) 2014-02-13
CN103328649B (zh) 2016-06-22
PT2643468T (pt) 2018-10-11

Similar Documents

Publication Publication Date Title
CY1121049T1 (el) Καινοτομες αλληλουχιες σηματος για τη βελτιωση των πρωτεϊνικων εκφρασεων και της εκκρισης των ανασυνδυασμενων ενζυμων και αλλων πρωτεϊνων
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
ATE527345T1 (de) Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten
CY1119755T1 (el) Πρωτεϊνες δεσμευομενες με ανθρωπινο αντιγονο c-fms
JP2016501535A5 (el)
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
NO20085253L (no) Enkelt-kjede multivalent bindingsproteiner med effektor funksjon
JP2014221801A5 (el)
DE602005027399D1 (de) Für humane matriptase spezifische bindungsproteine
MY162752A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
EA200870555A1 (ru) Слитые белки, их применение и способы их получения
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
EA201171259A1 (ru) Антительные гибридные белки с модифицированными сайтами связывания fcrn
IS2786B (is) Prótín sem bindast viðtaka Nogo
ATE488586T1 (de) In vitro peptid-expressionsbank
WO2006113546A3 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
JP2014503198A5 (el)
DE602005021750D1 (de) Impfstoffe mit lawsoniaintrazellularis-untereinheit
BRPI0411854A (pt) veìculos protéicos para vacinas
ATE474917T1 (de) Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
CY1117283T1 (el) Σταθερα μονομερη και ολιγομερη αμυλοειδους βητα
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
MX2021015698A (es) Integración dirigida de configuraciones aleatorias de ácidos nucleicos.
RU2010125678A (ru) Способ получения рекомбинантной вакцины
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof